Fluvoxamine

CHEMBL814 Phase 4 Aprobado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
318.3 g/mol
LogP
2.6
Phase
4

This selective serotonin reuptake inhibitor increases serotonin availability in the brain and is primarily used to treat obsessive-compulsive disorder as well as depression and anxiety disorders. It has also been studied for its potential anti-inflammatory effects in other conditions.

Peso molecular

318,3300 g/mol

LogP

2,60

TPSA

56,80 Ų

Regla de cinco de Lipinski

Cumple

Áreas terapéuticas

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Estructura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

COCCCC/C(=N\OCCN)c1ccc(C(F)(F)F)cc1

InChI

InChI=1S/C15H21F3N2O2/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18/h5-8H,2-4,9-11,19H2,1H3/b20-14+

Molecular Formula

C15H21F3N2O2

HBD / HBA

1 / 7

Enlaces Rotables

9

Átomos Pesados

22

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

This selective serotonin reuptake inhibitor increases serotonin availability in the brain and is primarily used to treat obsessive-compulsive disorder as well as depression and anxiety disorders. It has also been studied for its potential anti-inflammatory effects in other conditions.

Yes, Fluvoxamine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL814. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5324346. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.